6-Amino-1,3-Dimethyluracil in Pharmaceuticals

6-Amino-1,3-dimethyluracil (chemical formula C6H9N3O2, CAS number 6642 31 5) is a critical heterocyclic intermediate in pharmaceutical synthesis, valued for its unique pyrimidine core structure that enables the formation of diverse drug molecules. As a versatile building block, 6 amino 1 3 dimethyluracil serves as a precursor for antiviral, antibacterial, and anti-tumor drugs, playing a pivotal role in modern pharmaceutical R&D and production. Shijiazhuang Kunxiangda Technology Co., Ltd., established in 2011 and a professional manufacturer of pharmaceutical intermediates, specializes in high-purity 6 amino 1 3 dimethyluracil (6642 31 5) tailored for pharmaceutical applications. With a 50-acre facility in Shijiazhuang’s Economic and Technological Development Zone and a team of 9 technical experts, Kunxiangda ensures strict quality control aligned with global pharmaceutical standards, making it a trusted partner for wholesalers supplying drug manufacturers worldwide. For wholesalers, partnering with Kunxiangda means accessing C6H9N3O2 products optimized for pharmaceutical synthesis—backed by technical expertise, scalable bulk supply, and compliance with stringent regulatory requirements.

Core Pharmaceutical Applications of 6-Amino-1,3-Dimethyluracil

✦ Antiviral Drug Synthesis: 6 amino 1 3 dimethyluracil (6642 31 5) is a key intermediate in the production of nucleoside analog antiviral drugs, used to treat infections caused by herpes simplex virus (HSV), varicella-zoster virus (VZV), and hepatitis B virus (HBV). Its amino group enables selective modification of the pyrimidine ring, creating drugs that inhibit viral DNA replication. Kunxiangda’s C6H9N3O2 features a controlled impurity profile (≤0.1% related substances), ensuring high reaction selectivity and reducing toxic byproduct formation. A wholesaler supplying antiviral drug manufacturers reported that Kunxiangda’s 6 amino 1 3 dimethyluracil  improved drug yields by 25% compared to standard-grade intermediates, lowering production costs significantly.

✦ Anti-Tumor Agent Precursor: In oncology drug development, 6-amino-1,3-dimethyluracil serves as a building block for pyrimidine-based anti-tumor agents, which target rapidly dividing cancer cells by interfering with DNA synthesis. Its unique structure allows for the introduction of functional groups that enhance tumor cell specificity, reducing side effects in clinical applications. Kunxiangda’s technical team optimizes the particle size of 6 amino 1 3 dimethyluracil (6642 31 5) (80–120 mesh) for rapid dissolution in reaction media, accelerating drug synthesis cycles. A wholesaler serving oncology API manufacturers noted that this solubility advantage reduced reaction time by 30%, enabling faster development of life-saving cancer treatments.

Technical Requirements of 6-Amino-1,3-Dimethyluracil for Pharmaceutical Use

Advantages of Kunxiangda’s 6-Amino-1,3-Dimethyluracil for Wholesalers

✧ Regulatory Compliance Readiness: Pharmaceutical production requires strict adherence to global standards (FDA 21 CFR Part 211, ICH Q7 Good Manufacturing Practice). Kunxiangda’s 6 amino 1 3 dimethyluracil (6642 31 5) comes with comprehensive documentation, including batch-specific certificates of analysis (CoA), impurity profiles, GMP compliance statements, and stability data. This documentation streamlines regulatory filings for drug manufacturers, a critical advantage for wholesalers serving global pharmaceutical clients. A wholesaler supplying EU-based drugmakers reported that Kunxiangda’s compliance package reduced regulatory approval time by 40%, accelerating time-to-market for pharmaceutical products.

✧ Scalable Supply for Pharmaceutical Volumes: The high demand for antiviral and anti-tumor drugs requires consistent bulk supply of intermediates. Kunxiangda’s automated production lines support annual output of 6 amino 1 3 dimethyluracil exceeding 1,500 metric tons, with flexible batch sizes (50kg–3,000kg) to match wholesalers’ order requirements. The company’s 50-acre facility includes dedicated pharmaceutical-grade production zones, ensuring no cross-contamination with industrial-grade products. A wholesaler serving large-scale API manufacturers noted that this scalability eliminated stockout risks, with 99.8% on-time delivery rates for bulk orders.

Quality Control Measures for 6-Amino-1,3-Dimethyluracil

✦ In-Process Testing Protocols: Kunxiangda implements rigorous in-process testing during 6 amino 1 3 dimethyluracil (6642 31 5) production, including real-time monitoring of reaction temperature, pH, and purity. For pharmaceutical-grade C6H9N3O2, the company performs 15+ quality checks (from raw material intake to final packaging) to ensure compliance with drug synthesis requirements. This includes high-performance liquid chromatography (HPLC) for purity analysis and inductively coupled plasma mass spectrometry (ICP-MS) for heavy metal detection. A wholesaler supplying specialty pharmaceutical clients reported that these stringent controls reduced batch rejection rates by 60% compared to alternative suppliers.

✦ Stability Testing & Shelf Life Assurance: 6-amino-1,3-dimethyluracil must maintain chemical stability during storage to ensure consistent performance in drug synthesis. Kunxiangda conducts accelerated stability testing (40°C/75% RH for 6 months) and long-term stability testing (25°C/60% RH for 24 months) for all pharmaceutical-grade batches. The results confirm a 24-month shelf life for 6 amino 1 3 dimethyluracil (6642 31 5) when stored under recommended conditions, providing wholesalers with clear inventory management guidelines. A wholesaler with global distribution networks noted that this stability assurance reduced inventory waste by 35%, optimizing supply chain efficiency.

6-Amino-1,3-Dimethyluracil FAQS

What Purity Grade of 6-Amino-1,3-Dimethyluracil Is Required for Drug Synthesis?

Pharmaceutical drug synthesis mandates pharmaceutical-grade 6 amino 1 3 dimethyluracil (6642 31 5) with a minimum purity of 99.5%, as lower purity leads to the formation of toxic impurities that violate regulatory standards. Kunxiangda’s ultra-pure grade (≥99.8% purity) exceeds this requirement, with impurity levels ≤0.05% for key contaminants. A wholesaler supplying branded pharmaceutical manufacturers reported that this premium purity enabled compliance with EMA’s strict impurity limits (≤0.1% total impurities), avoiding costly regulatory delays.

How Does Kunxiangda Ensure Compatibility of 6-Amino-1,3-Dimethyluracil with Drug Synthesis Processes?

Kunxiangda’s 6 amino 1 3 dimethyluracil (6642 31 5) is specifically formulated for pharmaceutical synthesis, with a controlled particle size (80–120 mesh) for optimal solubility in common reaction media (e.g., dimethylformamide, ethanol). The company also provides application-specific technical data, including solubility curves, pKa values, and reaction kinetic parameters, to help manufacturers optimize process conditions. A wholesaler serving custom pharmaceutical synthesis clients noted that this compatibility support reduced process development time by 28%, enabling faster scale-up from lab to production.

Can 6-Amino-1,3-Dimethyluracil Be Used in Both Generic and Innovative Drug Production?

Yes—6 amino 1 3 dimethyluracil (6642 31 5) is versatile for both generic drug manufacturing (e.g., generic antiviral medications) and innovative drug R&D (e.g., novel anti-tumor agents). In generic production, its consistent quality ensures bioequivalence with branded drugs; in R&D, its high purity supports reliable experimental results. Kunxiangda’s technical team provides tailored recommendations for each use case, including custom purification options for innovative drug projects. A wholesaler supplying multi-technology pharmaceutical clients reported that this versatility increased order volume by 45%, as a single intermediate supported multiple production lines.

What Packaging Options Are Available for Pharmaceutical-Grade 6-Amino-1,3-Dimethyluracil?

Kunxiangda offers pharmaceutical-grade 6 amino 1 3 dimethyluracil (6642 31 5) in GMP-compliant packaging: 25kg heat-sealed HDPE bags (with desiccant packs) for small-batch orders, 50kg fiber drums (lined with food-grade polyethylene) for medium-volume supply, and 1000L IBC totes (pharmaceutical-grade liners) for large-scale API production. All packaging includes tamper-evident seals, batch labeling, and full compliance documentation. A wholesaler supplying global pharmaceutical distributors noted that the IBC tote option reduced shipping costs by 30% compared to drummed shipments, while maintaining product integrity.

How Does Kunxiangda Support Wholesalers in Regulatory Compliance for This Intermediate?

Kunxiangda provides wholesalers with a comprehensive compliance package for 6 amino 1 3 dimethyluracil (6642 31 5), including GMP certificates, batch CoAs, impurity profiles, stability data, and safety data sheets (SDS) aligned with global standards (FDA, EMA, ICH). The company’s 9 technical experts also offer consulting services for regulatory filings, helping wholesalers and their clients navigate complex pharmaceutical requirements. A wholesaler serving emerging market drug manufacturers reported that this compliance support simplified import approvals, reducing customs clearance time by 40% for international shipments.